Lenograstim is a recombinant form of human granulocyte colony-stimulating factor (G-CSF), primarily used to stimulate the production of neutrophils in patients undergoing chemotherapy or those with certain bone marrow disorders. It is characterized by its ability to enhance the proliferation and differentiation of hematopoietic stem cells, leading to increased white blood cell counts, particularly neutrophils. Lenograstim is typically administered via subcutaneous injection and is known for its relatively short half-life, necessitating regular dosing. The substance is produced using recombinant DNA technology, ensuring a high degree of purity and biological activity. Commonly, it is utilized in clinical settings to reduce the risk of infection in patients with neutropenia, thereby improving their overall treatment outcomes. Side effects may include bone pain, injection site reactions, and mild flu-like symptoms. As a biologic agent, lenograstim is subject to specific storage conditions to maintain its stability and efficacy.

Lenograstim

135968-09-1: Myelostim, Neutrogin, rG-CSF, Lenograstim, Granocyte

CAS 135968-09-1: Lenograstim

Lenograstim RS

Ref: 2K-1186200021